Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Notes Payables (2021 - 2025)

Ascendis Pharma A's Notes Payables history spans 3 years, with the latest figure at $438.0 million for Q4 2023.

  • For Q4 2023, Notes Payables rose 3591.46% year-over-year to $438.0 million; the TTM value through Dec 2023 reached $438.0 million, up 3591.46%, while the annual FY2023 figure was $440.4 million, 3492.59% up from the prior year.
  • Notes Payables for Q4 2023 was $438.0 million at Ascendis Pharma A, up from $11.9 million in the prior quarter.
  • Across five years, Notes Payables topped out at $438.0 million in Q4 2023 and bottomed at $8.0 million in Q4 2021.
  • The 3-year median for Notes Payables is $11.9 million (2022), against an average of $152.6 million.
  • The largest annual shift saw Notes Payables skyrocketed 48.28% in 2022 before it surged 3591.46% in 2023.
  • A 3-year view of Notes Payables shows it stood at $8.0 million in 2021, then surged by 48.28% to $11.9 million in 2022, then soared by 3591.46% to $438.0 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Notes Payables are $438.0 million (Q4 2023), $11.9 million (Q4 2022), and $8.0 million (Q4 2021).